title: Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.
abstract: This study was undertaken to quantify salivary gland parenchymal damage after radioiodine treatment with a standard protective regimen of ascorbic acid. Altogether, 106 patients underwent quantitative salivary gland scintigraphy with 99Tcm-pertechnetate prior to and 3 months after radioiodine therapy. Parenchymal function was quantified by calculating 99Tcm-pertechnetate uptake 13 min post-injection. Patients received 131I doses ranging from 400 MBq to 24 GBq (cumulative). Among the patients who received large doses of 131I, severe parenchymal destruction could be visually analysed as well as quantitatively evaluated. In contrast, after low-dose radioiodine treatment, mild parenchymal impairment was demonstrated by quantitative evaluation only. In conclusion, standardized quantitative salivary gland scintigraphy is essential for the reliable detection of mild parenchymal malfunction. Despite the standard protection regimen using ascorbic acid as a sialogogue, radioiodine therapy induces loss of salivary gland parenchymal function even with low doses of 131I.
authors.affiliation: Clinic of Nuclear Medicine, Christian-Albrechts-Universität Kiel, Germany.
authors.forename: K H
authors.initials: KH
authors.lastname: Bohuslavizki
authors.forename: W
authors.initials: W
authors.lastname: Brenner
authors.forename: S
authors.initials: S
authors.lastname: Lassmann
authors.forename: S
authors.initials: S
authors.lastname: Tinnemeyer
authors.forename: G
authors.initials: G
authors.lastname: Tönshoff
authors.forename: C
authors.initials: C
authors.lastname: Sippel
authors.forename: H
authors.initials: H
authors.lastname: Wolf
authors.forename: M
authors.initials: M
authors.lastname: Clausen
authors.forename: E
authors.initials: E
authors.lastname: Henze
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010306:Parotid Gland / Q000000981:diagnostic imaging / Q000293:injuries / Q000528:radiation effects; D011832:Radiation Injuries / Q000000981:diagnostic imaging* / Q000209:etiology*; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D012469:Salivary Glands / Q000000981:diagnostic imaging* / Q000293:injuries* / Q000528:radiation effects; D013670:Sodium Pertechnetate Tc 99m; D013363:Submandibular Gland / Q000000981:diagnostic imaging / Q000293:injuries / Q000528:radiation effects; D013959:Thyroid Diseases / Q000532:radiotherapy; D013964:Thyroid Neoplasms / Q000532:radiotherapy
chemical_list: D007457:Iodine Radioisotopes; D013670:Sodium Pertechnetate Tc 99m